Müller D - Search Results

1

A time-driven activity-based costing approach of magnetic resonance-guided high-intensity focused ultrasound for cancer-induced bone pain.

Simões Corrêa Galendi J, Yeo SY, Simic D, Grüll H, Stock S, Müller D. Simões Corrêa Galendi J, et al. Among authors: muller d. Int J Hyperthermia. 2022;39(1):173-180. doi: 10.1080/02656736.2021.2023768. Int J Hyperthermia. 2022. PMID: 35021942 Free article.

2

Life prolonging of disease management programs in patients with type 2 diabetes is cost-effective.

Drabik A, Büscher G, Sawicki PT, Thomas K, Graf C, Müller D, Stock S. Drabik A, et al. Among authors: muller d. Diabetes Res Clin Pract. 2012 Feb;95(2):194-200. doi: 10.1016/j.diabres.2011.09.015. Epub 2011 Oct 17. Diabetes Res Clin Pract. 2012. PMID: 22004943

3

Patients with type 2 diabetes benefit from primary care-based disease management: a propensity score matched survival time analysis.

Drabik A, Büscher G, Thomas K, Graf C, Müller D, Stock S. Drabik A, et al. Among authors: muller d. Popul Health Manag. 2012 Aug;15(4):241-7. doi: 10.1089/pop.2011.0063. Epub 2012 Mar 8. Popul Health Manag. 2012. PMID: 22401149

4

Cost-effectiveness analysis of FET PET-guided target selection for the diagnosis of gliomas.

Heinzel A, Stock S, Langen KJ, Müller D. Heinzel A, et al. Among authors: muller d. Eur J Nucl Med Mol Imaging. 2012 Jul;39(7):1089-96. doi: 10.1007/s00259-012-2093-0. Epub 2012 Mar 15. Eur J Nucl Med Mol Imaging. 2012. PMID: 22419257

5

Cost-effectiveness analysis of amino acid PET-guided surgery for supratentorial high-grade gliomas.

Heinzel A, Stock S, Langen KJ, Müller D. Heinzel A, et al. Among authors: muller d. J Nucl Med. 2012 Apr;53(4):552-8. doi: 10.2967/jnumed.111.097352. Epub 2012 Mar 14. J Nucl Med. 2012. PMID: 22419752 Free article.

6

Cost effectiveness of rituximab for non-Hodgkin's lymphoma: a systematic review.

Auweiler PW, Müller D, Stock S, Gerber A. Auweiler PW, et al. Among authors: muller d. Pharmacoeconomics. 2012 Jul 1;30(7):537-49. doi: 10.2165/11591160-000000000-00000. Pharmacoeconomics. 2012. PMID: 22612993 Review.

7

A multi-perspective cost-effectiveness analysis comparing rivaroxaban with enoxaparin sodium for thromboprophylaxis after total hip and knee replacement in the German healthcare setting.

Zindel S, Stock S, Müller D, Stollenwerk B. Zindel S, et al. Among authors: muller d. BMC Health Serv Res. 2012 Jul 9;12:192. doi: 10.1186/1472-6963-12-192. BMC Health Serv Res. 2012. PMID: 22776616 Free PMC article.

8

[Cost of illness of age-related macular degeneration. Systematic review on the development of a costs diary].

Gibbert J, Müller D, Fauser S, Stock S. Gibbert J, et al. Among authors: muller d. Ophthalmologe. 2013 Jun;110(6):528-36. doi: 10.1007/s00347-012-2750-5. Ophthalmologe. 2013. PMID: 23297119 Review. German.

9

Cost-effectiveness of a multifactorial fracture prevention program for elderly people admitted to nursing homes.

Müller D, Borsi L, Stracke C, Stock S, Stollenwerk B. Müller D, et al. Eur J Health Econ. 2015 Jun;16(5):517-27. doi: 10.1007/s10198-014-0605-5. Epub 2014 May 13. Eur J Health Econ. 2015. PMID: 24818587

10

Cost effectiveness of rivaroxaban for stroke prevention in German patients with atrial fibrillation.

Mensch A, Stock S, Stollenwerk B, Müller D. Mensch A, et al. Among authors: muller d. Pharmacoeconomics. 2015 Mar;33(3):271-83. doi: 10.1007/s40273-014-0236-9. Pharmacoeconomics. 2015. PMID: 25404426

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

4,982 results

Search Page

Filters